Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock
Summary
Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members.
I-Mab's shares have nearly doubled over the past six months on the major…